... preclinical and clinicalpharmacokinetic and pharmacodynamic data. J Clin Oncol 2008,26:1596-1602.17. Okamoto I, Doi T, Ohtsu A, Miyazaki M, Tsuya A, Kurei K, Kobayashi K,Nakagawa K: Phase ... the patient with breast cancer.PharmacokineticsAbsorption of everolimus after oral administration wasrapid to moderate with a median Tmax of 3.0 h in the 5mg/daycohortand2.0hinthe10mg/daycohort(Figure ... safe ty, and efficacy of the oral mammalian target of rapamycin inhibitor everolimus in Chinese patients with advancedsolid tumors.Methods: A total of 24 patients with advance d breast cancer...